Abiopharma

🔍 Karros Kirt P (Executive)

Company: Hewlett Packard Enterprise Co (HPE)

Report Date: 2026-06-20

Detailed Transactions and Holdings:

• Sold 18,785 shares of Common Stock at $48.5 per share (Direct)
  Date: 2026-06-22 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4
• Acquired 364 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 33,057.41 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F2, F2
• Acquired 593 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 52,391.11 | transaction_form_type: 4 | Footnotes: F1, F3, F3, F3, F3
• Acquired 1,391 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 120,488.88 | transaction_form_type: 4 | Footnotes: F1, F4, F4, F4, F4
• Acquired 985 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 84,806.78 | transaction_form_type: 4 | Footnotes: F1, F5, F5, F5, F5
• Acquired 21,093 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-20 | Code: A | equity_swap_involved: 0 | shares_owned_after: 21,093.00 | transaction_form_type: 4 | Footnotes: F1, F6, F6, F6, F6

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
• F2: As previously reported, on 12/07/23, the reporting person was granted 93,052 Restricted Stock Units ("RSUs"), 31,017 of which vested on 12/07/24, 31,017 of which vested on 12/07/25, and 31,018 of which will vest on 12/07/26. Dividend equivalent rights accrue with respect to these RSUs when and as dividends are paid on Issuer's common stock. The number of derivative securities in column 5 reflects 206.1597 dividend equivalent rights at $21.44 per RSU credited to the reporting person's account on 01/16/26, and 158.2551 dividend equivalent rights at $27.93 per RSU credited to the reporting person's account on 04/23/26.
• F3: As previously reported, on 12/09/24, the reporting person was granted 75,725 RSUs, 25,241 of which vested on 12/09/25, and 25,242 of which will vest on each of 12/09/26 and 12/09/27. The number of derivative securities in column 5 reflects 335.5396 dividend equivalent rights at $21.44 per RSU credited to the reporting person's account on 01/16/26, and 257.5714 dividend equivalent rights at $27.93 per RSU credited to the reporting person's account on 04/23/26.
• F4: As previously reported, on 07/20/25, the reporting person was granted 118,427 RSUs, 39,475 of which will vest on 07/20/26, and 39,476 of which will vest on each of 07/20/27 and 07/20/28. The number of derivative securities in column 5 reflects 787.1198 dividend equivalent rights at $21.44 per RSU credited to the reporting person's account on 01/16/26, and 604.2194 dividend equivalent rights at $27.93 per RSU credited to the reporting person's account on 04/23/26.
• F5: As previously reported, on 12/08/25, the reporting person was granted 83,822 RSUs, 27,940 of which will vest on 12/08/26, and 27,941 of which will vest on each of 12/08/27 and 12/08/28. Dividend equivalent rights accrue with respect to these RSUs when and as dividends are paid on Issuer's common stock. The number of derivative securities in column 5 reflects 557.1192 dividend equivalent rights at $21.44 per RSU credited to the reporting person's account on 01/16/26, and 427.6633 dividend equivalent rights at $27.93 per RSU credited to the reporting person's account on 04/23/26.
• F6: On 06/20/26, the reporting person was granted 21,093 RSUs, 7,031 of which will vest on each of 06/20/27, 06/20/28, and 06/20/29. Dividend equivalent rights accrue with respect to these RSUs when and as dividends are paid on Issuer's common stock.
• REMARKS: The reported transaction occurred pursuant to a trading plan adopted on 03/23/26.